What happened
Prestige Biologics updated the terms of convertible bonds to raise US$29.6M, about 41.2% of its market value.
For context, this raise equals about 41.2% of the company's market value, which is the rough scale of potential new-share dilution.
| Instrument | Convertible bonds |
|---|---|
| Raise amount | US$29.6M |
| vs. market value | 41.2% |
| Filed | 2026-06-22, [Amended] Material event report (convertible bonds) |
| Source | DART rcept 20260622000362 → open original filing |
Source: DART. Information only, not investment advice.